| AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer DAE Cross, SE Ashton, S Ghiorghiu, C Eberlein, CA Nebhan, PJ Spitzler, ... Cancer discovery 4 (9), 1046-1061, 2014 | 2088 | 2014 |
| CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma CW Steele, SA Karim, JDG Leach, P Bailey, R Upstill-Goddard, L Rishi, ... Cancer cell 29 (6), 832-845, 2016 | 755 | 2016 |
| Acquired resistance to the mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models CA Eberlein, D Stetson, AA Markovets, KJ Al-Kadhimi, Z Lai, PR Fisher, ... Cancer research 75 (12), 2489-2500, 2015 | 317 | 2015 |
| Structure-and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR) RA Ward, MJ Anderton, S Ashton, PA Bethel, M Box, S Butterworth, ... Journal of medicinal chemistry 56 (17), 7025-7048, 2013 | 262 | 2013 |
| AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014; 4: 1046–1061. doi: 10.1158/2159-8290 DA Cross, SE Ashton, S Ghiorghiu, C Eberlein, CA Nebhan, PJ Spitzler, ... CD-14-0337.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 131 | |
| AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014; 4: 1046–1061. doi: 10.1158/2159-8290 DA Cross, SE Ashton, S Ghiorghiu, C Eberlein, CA Nebhan, PJ Spitzler, ... CD-14-0337.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 131 | |
| A human monoclonal antibody 264RAD targeting αvβ6 integrin reduces tumour growth and metastasis, and modulates key biomarkers in vivo C Eberlein, J Kendrew, K McDaid, A Alfred, JS Kang, VN Jacobs, SJ Ross, ... Oncogene 32 (37), 4406-4416, 2013 | 96 | 2013 |
| In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib MG Rolf, JO Curwen, M Veldman‐Jones, C Eberlein, J Wang, A Harmer, ... Pharmacology research & perspectives 3 (5), e00175, 2015 | 84 | 2015 |
| MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis In Vivo DW Jenkins, S Ross, M Veldman-Jones, IN Foltz, BC Clavette, ... Molecular cancer therapeutics 11 (8), 1650-1660, 2012 | 64 | 2012 |
| E-Cadherin and EpCAM expression by NSCLC tumour cells associate with normal fibroblast activation through a pathway initiated by integrin αvβ6 and maintained through TGFβ … C Eberlein, C Rooney, SJ Ross, M Farren, HM Weir, ST Barry Oncogene 34 (6), 704-716, 2015 | 59 | 2015 |
| An antibody targeted to VEGFR-2 Ig domains 4-7 inhibits VEGFR-2 activation and VEGFR-2–dependent angiogenesis without affecting ligand binding J Kendrew, C Eberlein, B Hedberg, K McDaid, NR Smith, HM Weir, ... Molecular Cancer Therapeutics 10 (5), 770-783, 2011 | 45 | 2011 |
| Optimizing the Sequence of Anti-EGFR–Targeted Therapy in EGFR-Mutant Lung Cancer CB Meador, H Jin, E de Stanchina, CA Nebhan, V Pirazzoli, L Wang, P Lu, ... Molecular cancer therapeutics 14 (2), 542-552, 2015 | 38 | 2015 |
| Abstract A109: AZD9291: an irreversible, potent and selective third generation tyrosine kinase inhibitor (TKI) targeting EGFR activating (EGFRm+) and resistance (T790M … D Cross, S Ashton, C Nebhan, C Eberlein, MRV Finlay, G Hughes, ... Molecular Cancer Therapeutics 12 (11_Supplement), A109-A109, 2013 | 26 | 2013 |
| Combined inhibition of PI3Kβ and mTOR inhibits growth of PTEN-null tumors JT Lynch, UM Polanska, U Hancox, O Delpuech, J Maynard, C Trigwell, ... Molecular Cancer Therapeutics 17 (11), 2309-2319, 2018 | 24 | 2018 |
| Mixed micelles of lipoic acid-chitosan-poly (ethylene glycol) and distearoylphosphatidylethanolamine-poly (ethylene glycol) for tumor delivery Z Elsaid, KMG Taylor, S Puri, CA Eberlein, K Al-Jamal, J Bai, R Klippstein, ... European Journal of Pharmaceutical Sciences 101, 228-242, 2017 | 22 | 2017 |
| Leptin, BMI, and a metabolic gene expression signature associated with clinical outcome to VEGF inhibition in colorectal cancer AJC Pommier, M Farren, B Patel, M Wappett, F Michopoulos, NR Smith, ... Cell metabolism 23 (1), 77-93, 2016 | 21 | 2016 |
| 2014 DA Cross, SE Ashton, S Ghiorghiu, C Eberlein, CA Nebhan, PJ Spitzler 4 10, 1158, 2016 | 19 | 2016 |
| Placental growth factor neutralising antibodies give limited anti-angiogenic effects in an in vitro organotypic angiogenesis model SR Brave, C Eberlein, M Shibuya, SR Wedge, ST Barry Angiogenesis 13, 337-347, 2010 | 18 | 2010 |
| Utilization of structure-based design to identify novel, irreversible inhibitors of EGFR harboring the T790M mutation EJ Hennessy, C Chuaqui, S Ashton, N Colclough, DAE Cross, ... ACS Medicinal Chemistry Letters 7 (5), 514-519, 2016 | 11 | 2016 |
| AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors S Dunn, C Eberlein, J Yu, A Gris-Oliver, SH Ong, U Yelland, N Cureton, ... Oncogene 41 (46), 5046-5060, 2022 | 10 | 2022 |
